Progynon Associates, et al.; Withdrawal of Approval of Four New Drug Applications

الملخص

The Food and Drug Administration (FDA) is withdrawing approval of four new drug applications (NDAs) from multiple holders of those NDAs. The basis for the withdrawal is that these NDA holders have repeatedly failed to file required annual reports for the identified NDAs.